| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 1.5 |
| Total income | 0.0 | 0.0 | 1.5 |
| Profit before exceptional items & tax | -1.3 | -7.8 | -1.5 |
| Profit before tax | -1.3 | -7.8 | -1.5 |
| Net profit | -1.0 | -5.9 | -1.3 |
| Operating margin | 0.0% | 0.0% | -100.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: VISTAPH. Figures extracted from the filing.
Vista Pharmaceuticals Ltd: key numbers
- Share price
- ₹6.40
- Market cap
- ₹39.39 Cr
- Revenue (annual)
- ₹5.40 Cr
- Net profit (annual)
- ₹-12.06 Cr
- P/E (TTM)
- -3.4×Sector 47.4×
- Promoter holding
- 21.19%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vista Pharmaceuticals Ltd
All →Vista Pharmaceuticals Management Change
Vista Pharmaceuticals Ltd announced the resignation of Mrs. Barkha Jain as Company Secretary and Compliance Officer, effective September 4, 2026.
Vista Pharmaceuticals Board Meeting Date
Vista Pharmaceuticals has scheduled a board meeting for August 14, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.
Vista Pharmaceuticals Other Announcement
Vista Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Vista Pharmaceuticals Other Announcement
Vista Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no material deviations.
Vista Pharmaceuticals Q4 FY26 Results: Net Loss of ₹5.9 Cr, Loss Widens
Vista Pharmaceuticals Ltd reported a net loss of ₹5.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹5.9 Cr
Vista Pharmaceuticals Financial Results
Vista Pharmaceuticals reported audited financial results for the year ended March 31, 2026. The company also appointed M/s. LMN & Co. as internal auditors.